bictegravir
State of the ART: HIV Management in 2025
Earlier initiation of ART and better medication options have resulted in a narrowing in the mortality gap between ...
JULY 3, 2025
Crushing/Dissolving HIV Medication Effective for Hospitalized Patients
Providing dissolved or crushed Biktarvy through an enteral tube can achieve viral suppression and may be a good ...
JUNE 27, 2025
Biktarvy’s Benefits Extend in Older Adults With HIV
Five-year follow-up data from the triple combination HIV therapy bictegravir-emtricitabine-tenofavir alafenamide ...
NOVEMBER 25, 2024
Bictegravir and Lenacapavir an Effective ART Switch for People With HIV
A novel combination of bictegravir and lenacapavir appears highly effective in maintaining viral suppression over ...
JULY 26, 2024
Faster Viral Suppression With Biktarvy Among Patients With Advanced HIV
Biktarvy is associated with faster CD4 cell count recovery and favorable virologic outcomes compared with other ...
MAY 5, 2023
Biktarvy Could Be Long-Term Option for Older Adults With HIV
Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF; Biktarvy, Gilead) could be a long-term option for ...
OCTOBER 6, 2022
Biktarvy Demonstrates High Efficacy, Tolerability Through 96 Weeks
Gilead reported 96 week results for a comparative trial of Biktarvy in HIV patients who were treatment naive.
OCTOBER 9, 2018
Switching HIV Regimen Found Safe
Switching to the newly approved Biktarvy in virologically suppressed adults maintained viral suppression with fewer ...
MARCH 7, 2018
ViiV Files Suit Against Gilead Over HIV Drug Patents
ViiV claims bictegravir infringes on its patent covering dolutegravir and many other compounds that include ...
FEBRUARY 8, 2018
Bictegravir-Containing Compound Found Noninferior in Phase 3 Trial
Bictegravir is a novel, potent integrase strand transfer inhibitor (INSTI), which features a high in vitro barrier ...
OCTOBER 10, 2017
Good Virologic Response Seen for Bictegravir in HIV
News from CROI 2017: Gilead's novel, investigational drug appears to be promising in rapidly suppressing HIV.
FEBRUARY 15, 2017
